- Home
- DVAX vs FINW Comparison
DVAX vs FINW Comparison
Compare DVAX & FINW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DVAX
- FINW
- Stock Information
- Founded
- DVAX 1996
- FINW 1999
- Country
- DVAX United States
- FINW United States
- Employees
- DVAX N/A
- FINW N/A
- Industry
- DVAX Biotechnology: Pharmaceutical Preparations
- FINW Commercial Banks
- Sector
- DVAX Health Care
- FINW Finance
- Exchange
- DVAX Nasdaq
- FINW Nasdaq
- Market Cap
- DVAX 1.2B
- FINW 242.1M
- IPO Year
- DVAX 2004
- FINW 2021
- Fundamental
- Price
- DVAX $10.56
- FINW $18.13
- Analyst Decision
- DVAX Buy
- FINW Buy
- Analyst Count
- DVAX 4
- FINW 4
- Target Price
- DVAX $26.50
- FINW $20.75
- AVG Volume (30 Days)
- DVAX 1.3M
- FINW 14.4K
- Earning Date
- DVAX 11-05-2025
- FINW 10-29-2025
- Dividend Yield
- DVAX N/A
- FINW N/A
- EPS Growth
- DVAX N/A
- FINW N/A
- EPS
- DVAX N/A
- FINW 0.96
- Revenue
- DVAX $316,268,000.00
- FINW $74,999,000.00
- Revenue This Year
- DVAX $23.23
- FINW $52.89
- Revenue Next Year
- DVAX $16.57
- FINW $20.66
- P/E Ratio
- DVAX N/A
- FINW $18.86
- Revenue Growth
- DVAX 26.66
- FINW 10.21
- 52 Week Low
- DVAX $9.20
- FINW $13.49
- 52 Week High
- DVAX $14.63
- FINW $22.49
- Technical
- Relative Strength Index (RSI)
- DVAX 62.66
- FINW 43.28
- Support Level
- DVAX $10.03
- FINW $17.49
- Resistance Level
- DVAX $10.12
- FINW $18.22
- Average True Range (ATR)
- DVAX 0.22
- FINW 0.43
- MACD
- DVAX 0.07
- FINW -0.02
- Stochastic Oscillator
- DVAX 100.00
- FINW 35.75
About DVAX Dynavax Technologies Corporation
Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of HEPLISAV-B (Hepatitis B Vaccine (Recombinant), Adjuvanted), operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product and HEPLISAV-B.
About FINW FinWise Bancorp
FinWise Bancorp is an independent bank that provides a full range of banking services to individual and corporate customers. The bank's primary source of revenue is from loans, including Small Business Administration, commercial, commercial real estate, residential real estate, and consumer. The Bank has also established Strategic Programs with various third-party loan origination platforms that use technology to streamline the origination of unsecured consumer and secured or unsecured business loans to borrowers within certain approved credit profiles.